Germany debates breast cancer screening programme:
This article was originally published in Clinica
Executive Summary
A forum established to co-ordinate a European programme to fight breast cancer last week concentrated on how a screening programme could speedily be introduced to Germany. By the end of 2003, experts hope to have introduced across the country a quality-assured screening programme based on European guidelines. Results from a number of German projects, started six months ago, were presented at the forum. Dr Margrit Reichel, who ran one of the projects in Wiesbaden, said that some 3,400 women had taken part, roughly half of those who had been invited. "The women screened were between the ages of 50-69," she told Clinica. 50 breast cancers have so far been detected, she said, a higher number than expected. This had made the projects a genuine success.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.